The cholesterol-lowering drug ezetimbe, sold as Zetia and in
combination with the statin Zocor as Vytorin, has proved no
better at reducing plaque than the statin alone, and may be
linked to an increased risk of cancer.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.